What do you when you are so clearly successful? When you have crushed your rivals and left them preventing around crumbs? If you are Illumina, the biotech large whose name has develop into synonymous with DNA sequencing devices, you glance close to and place some of your extra dollars in a startup seeking to make better wine. Or more healthy dairy cows. Or wise tampons. These are all industries Illumina thinks can reward from an inflow of genetic sequencing, and these are all genuine startups that have gone through Illumina Accelerator, which nurtures young corporations with dollars, San Francisco office environment place, and access to its DNA sequencing devices. These days, Illumina is saying the two associates in the fourth spherical of its accelerator system: REX, a Kansas Town-primarily based animal wellbeing firm and the Centre of Individualized Diagnostics, a genomics heart in Saudi Arabia. There is a process to this eclecticism. Illumina these days dominates a decently sized pie, marketing DNA sequencing devices to research labs. If Illumina could also market its devices to medical professionals and hospital labs and agriculture corporations, then that pie could get a heck of a ton larger. The entire issue of the accelerator system is to find new apps for its know-how. REX is a big details animal wellbeing firm, and with Illumina’s assist, it is now seeking to monitor livestock for genes that confer disease resistance. The other grantee this cycle, the Centre of Individualized Diagnostics, expands Illumina’s access geographically, bringing significant-throughput genetic checks to Saudi Arabia, a nation not automatically on the reducing edge of biotech. With the accelerator, Illumina can make smaller bets on risky tips. The accelerator is element of a lengthy line of Illumina’s moves towards the application aspect of DNA sequencing. In 2013, it obtained a firm that sells genetic checks for toddlers, and invested in Helix, an app keep for genetic details, in 2015. And maybe its most bold transfer is spinning off Grail, a firm that will provide liquid biopsies to diagnose most cancers. Illumina is looking much in advance with Grail. Only a small fraction of folks have had their genomes sequenced so much, but eventually that market place will be saturated. You only need your genome sequenced as soon as. But with Grail, which will glance for tumor DNA in the blood, sufferers could appear again all over again and all over again for program checks. That is a ton of tests—and a ton of devices to operate those checks on. Illumina is not alone in eyeing the market place for genetic checks, suggests Stephane Budel, a companion at the market place research agency DeciBio. “A ton of lifestyle sciences suppliers have understood the cash is not in the resources themselves, but the cash is in the apps.” He factors to Thermo Fisher, one of Illumina’s main rivals in DNA sequencers, which has since pivoted to giving diagnostics. Illumina is hedging its bets, continuing to increase its components business enterprise and acquiring in on the diagnostics action. Amanda Cashin, head of Illumina Accelerator, suggests the system would shy away from startups instantly competing with Grail. But other than that, they are eager to exam out new and unpredicted tips. Agriculture has in fact been big place of desire. 4 of the twelve corporations accepted to the accelerator on the earlier two yrs have been in the ag bio place. “Human wellbeing is extra superior than animal,” suggests REX founder Amado Guloy, “and that’s really fantastic.” It is an opportunity to acquire all the concepts gleaned from the human microbiome and utilize it to animals or even plants. Before Cashin started off Illumina’s accelerator, she served operate a undertaking funds fund in biotech for Alexandria. Her connections in the undertaking funds community appear in handy for the startups she’s advising now. But Alexandria is essentially a genuine estate firm, which specializes in developing lab and office environment place for lifestyle sciences hubs like Boston, San Diego, and the really offices that dwelling the accelerator in San Francisco’s Mission Bay. Alexandria creates communities close to lifestyle science companies—now Illumina is seeking to do the same with genetic sequencing corporations.
Source url Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)Click to share on Google+ (Opens in new window)
Related
What do you when you are so clearly successful? When you have crushed your rivals and left them preventing around crumbs? If you are Illumina, the biotech large whose name has develop into synonymous with DNA sequencing devices, you glance close to and place some of your extra dollars in a startup seeking to make better wine. Or more healthy dairy cows. Or wise tampons.
These are all industries Illumina thinks can reward from an inflow of genetic sequencing, and these are all genuine startups that have gone through Illumina Accelerator, which nurtures young corporations with dollars, San Francisco office environment place, and access to its DNA sequencing devices. These days, Illumina is saying the two associates in the fourth spherical of its accelerator system: REX, a Kansas Town-primarily based animal wellbeing firm and the Centre of Individualized Diagnostics, a genomics heart in Saudi Arabia.
There is a process to this eclecticism. Illumina these days dominates a decently sized pie, marketing DNA sequencing devices to research labs. If Illumina could also market its devices to medical professionals and hospital labs and agriculture corporations, then that pie could get a heck of a ton larger. The entire issue of the accelerator system is to find new apps for its know-how.
REX is a big details animal wellbeing firm, and with Illumina’s assist, it is now seeking to monitor livestock for genes that confer disease resistance. The other grantee this cycle, the Centre of Individualized Diagnostics, expands Illumina’s access geographically, bringing significant-throughput genetic checks to Saudi Arabia, a nation not automatically on the reducing edge of biotech. With the accelerator, Illumina can make smaller bets on risky tips.
The accelerator is element of a lengthy line of Illumina’s moves towards the application aspect of DNA sequencing. In 2013, it obtained a firm that sells genetic checks for toddlers, and invested in Helix, an app keep for genetic details, in 2015. And maybe its most bold transfer is spinning off Grail, a firm that will provide liquid biopsies to diagnose most cancers.
Illumina is looking much in advance with Grail. Only a small fraction of folks have had their genomes sequenced so much, but eventually that market place will be saturated. You only need your genome sequenced as soon as. But with Grail, which will glance for tumor DNA in the blood, sufferers could appear again all over again and all over again for program checks. That is a ton of tests—and a ton of devices to operate those checks on.
Illumina is not alone in eyeing the market place for genetic checks, suggests Stephane Budel, a companion at the market place research agency DeciBio. “A ton of lifestyle sciences suppliers have understood the cash is not in the resources themselves, but the cash is in the apps.” He factors to Thermo Fisher, one of Illumina’s main rivals in DNA sequencers, which has since pivoted to giving diagnostics. Illumina is hedging its bets, continuing to increase its components business enterprise and acquiring in on the diagnostics action.
Amanda Cashin, head of Illumina Accelerator, suggests the system would shy away from startups instantly competing with Grail. But other than that, they are eager to exam out new and unpredicted tips. Agriculture has in fact been big place of desire. 4 of the twelve corporations accepted to the accelerator on the earlier two yrs have been in the ag bio place. “Human wellbeing is extra superior than animal,” suggests REX founder Amado Guloy, “and that’s really fantastic.” It is an opportunity to acquire all the concepts gleaned from the human microbiome and utilize it to animals or even plants.
Before Cashin started off Illumina’s accelerator, she served operate a undertaking funds fund in biotech for Alexandria. Her connections in the undertaking funds community appear in handy for the startups she’s advising now. But Alexandria is essentially a genuine estate firm, which specializes in developing lab and office environment place for lifestyle sciences hubs like Boston, San Diego, and the really offices that dwelling the accelerator in San Francisco’s Mission Bay. Alexandria creates communities close to lifestyle science companies—now Illumina is seeking to do the same with genetic sequencing corporations.